RFP – Nonhuman Primate Virology Laboratory for AIDS Vaccine Research

HIV particles infecting a human H9 T-cellThe National Institute of Allergy and Infectious Diseases (NIAID) is seeking proposals from organizations capable of conducting quantitative viral RNA measurements for assessment of HIV/SIV vaccine efficacy in preclinical studies with nonhuman primates.

NIAID provides immunological and virological support for nonhuman primate studies conducted at NIAID’s Simian Vaccine Evaluation Unit (SVEU) contract sites and by AIDS vaccine researchers through three Nonhuman Primate Immunology and Virology Laboratories for AIDS Vaccine Research and Development, previously called the NHP “Core Laboratories.”

The objective of the Core Laboratories has been to ensure standardization and comparability of the assays conducted for preclinical NHP studies and to provide a common basis for assessment of the immunogenicity and efficacy of candidate HIV and SIV vaccines.

Advanced BioScience Laboratories, Inc. holds the current contract for the Nonhuman Primate Core Virology Laboratory for AIDS Vaccine Research and Development (HHSN272201100022C).

The purpose of the proposed contract is to provide a NHP virology laboratory that will conduct quantitative viral RNA measurements in support of studies that evaluate prototype AIDS vaccines in nonhuman primates.

The contract will support the conduct, improvement, and development of assays designed to measure viral RNA loads in nonhuman primates that have been immunized with candidate HIV or SIV vaccines and challenged with SIV or SHIV in studies conducted at DAIDS Simian Vaccine Evaluation Unit contract sites or by NIH-supported investigators.

It is anticipated that one cost reimbursement, term type contract will be awarded for a 1-year Base period plus six 1-year options for a possible total period of performance of 7 years beginning on or about December 29, 2017.

Further details are available via Solicitation Number: NIAID-DAIDS-NIHAI2016075. The response deadline is February 15, 2017.

From Our Partners

More From Global Biodefense